Spyre Therapeutics, Inc. $SYRE Shares Bought by B Group Inc.

B Group Inc. increased its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 25.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 100,000 shares of the company’s stock after buying an additional 20,000 shares during the period. Spyre Therapeutics comprises approximately 1.3% of B Group Inc.’s holdings, making the stock its 11th biggest position. B Group Inc. owned 0.17% of Spyre Therapeutics worth $1,676,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of SYRE. Affinity Asset Advisors LLC boosted its stake in shares of Spyre Therapeutics by 26.0% during the 2nd quarter. Affinity Asset Advisors LLC now owns 606,678 shares of the company’s stock worth $9,082,000 after acquiring an additional 125,000 shares in the last quarter. Candriam S.C.A. grew its position in Spyre Therapeutics by 64.4% during the third quarter. Candriam S.C.A. now owns 404,362 shares of the company’s stock valued at $6,777,000 after purchasing an additional 158,332 shares in the last quarter. AlphaQuest LLC grew its stake in Spyre Therapeutics by 1,485.1% in the third quarter. AlphaQuest LLC now owns 66,163 shares of the company’s stock valued at $1,109,000 after purchasing an additional 61,989 shares in the last quarter. Franklin Resources Inc. increased its holdings in Spyre Therapeutics by 4.6% in the second quarter. Franklin Resources Inc. now owns 795,275 shares of the company’s stock worth $11,905,000 after buying an additional 34,647 shares during the last quarter. Finally, Intech Investment Management LLC increased its holdings in Spyre Therapeutics by 22.1% in the second quarter. Intech Investment Management LLC now owns 24,945 shares of the company’s stock worth $373,000 after buying an additional 4,517 shares during the last quarter. Institutional investors and hedge funds own 80.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on SYRE shares. Leerink Partners upgraded Spyre Therapeutics to a “strong-buy” rating in a report on Thursday, February 19th. Wells Fargo & Company increased their price objective on Spyre Therapeutics from $40.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, February 20th. Mizuho raised shares of Spyre Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Citigroup initiated coverage on shares of Spyre Therapeutics in a research note on Wednesday, December 17th. They issued a “buy” rating and a $64.00 target price on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Spyre Therapeutics in a report on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Spyre Therapeutics presently has an average rating of “Buy” and a consensus price target of $53.44.

Spyre Therapeutics Trading Down 1.3%

Shares of NASDAQ SYRE opened at $39.89 on Friday. Spyre Therapeutics, Inc. has a 12 month low of $10.91 and a 12 month high of $45.76. The stock has a 50 day moving average of $36.06 and a 200-day moving average of $27.94. The company has a market capitalization of $3.13 billion, a P/E ratio of -19.18 and a beta of 3.09.

Spyre Therapeutics (NASDAQ:SYRE) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.04). Analysts predict that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Scott L. Burrows sold 2,500 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $40.65, for a total value of $101,625.00. Following the completion of the transaction, the chief financial officer owned 97,994 shares of the company’s stock, valued at $3,983,456.10. The trade was a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Cameron Turtle sold 15,000 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $42.19, for a total transaction of $632,850.00. Following the completion of the transaction, the chief executive officer directly owned 642,540 shares in the company, valued at approximately $27,108,762.60. This represents a 2.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 47,500 shares of company stock worth $1,686,675 in the last three months. 15.43% of the stock is currently owned by company insiders.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.